Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{204642,
        author = {B Harshavardini},
        title = {Trade-Related Aspects of Intellectual Property Rights And Regulatory Auditing: Current Trends And Challenges in D-8 Countries},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {3429-3432},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=204642},
        abstract = {Background: Intellectual Property Rights (IPR) and regulatory auditing are fundamental pillars supporting innovation, pharmaceutical quality, and international trade. The Developing Eight (D-8) countries—Bangladesh, Egypt, Indonesia, Iran, Malaysia, Nigeria, Pakistan, and Turkey—have established diverse regulatory and intellectual property frameworks to enhance industrial growth and public health protection.
Objective: To evaluate the current status of Intellectual Property Rights and regulatory auditing systems among D-8 countries, compare regulatory practices, and identify challenges affecting pharmaceutical innovation, compliance, and trade competitiveness.
Methods: A comparative review-based study was conducted using published literature, regulatory guidelines, intellectual property laws, and trade-related information available across D-8 nations. Data regarding patent validity, trademark protection, regulatory authorities, audit procedures, and international agreements were analyzed descriptively.
Results: The study revealed substantial variations in regulatory infrastructure, intellectual property enforcement, and audit mechanisms among D-8 countries. Most nations comply with Trade-Related Aspects of Intellectual Property Rights (TRIPS) requirements by providing patent protection for approximately 20 years. Regulatory authorities such as DGDA, EDA, BPOM, FDA-Iran, NPRA, NAFDAC, DRAP, and TITCK play vital roles in maintaining pharmaceutical quality through inspections and audits. However, limitations including inadequate resources, lack of technical expertise, weak enforcement systems, lengthy approval timelines, and regulatory disparities continue to affect effective implementation.
Conclusion: Strengthening regulatory harmonization, enhancing intellectual property enforcement, improving audit quality, and increasing international collaboration among D-8 nations can promote pharmaceutical innovation, improve public health outcomes, and enhance global competitiveness.},
        keywords = {Intellectual Property Rights, Regulatory Auditing, D-8 Countries, TRIPS, Pharmaceutical Industry, Patents, Trade Regulations.},
        month = {June},
        }